An Extension of the TG1101-RMS201 Trial
We could not find results for this trial
I know where the results areWhat it found
We found no results in the registry or in papers.
This trial finished 3 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Ublituximab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
Number of participants with treatment-related events as assessed by CTCAE V4.0
96 weeks on therapy
Safety
Other measures (1)
Evaluate the % of participants with relapses
up to 96 Weeks
Relapses
Who could take part
Relapsing MS · 18 to 55
Inclusion Criteria: * Subjects currently enrolled in TG1101-RMS201 trial * Subjects who have completed three infusions of ublituximab (at Day 1, Day 15, and Week24, as specified in the TG1101-RMS201 protocol) and have completed the scheduled assessments up to the final 48-week visit Exclusion Criteria: * Subjects who discontinued ublituximab treatment or withdrew consent from the TG1101- RMS201 study during the 48-week evaluation period * Subjects who have started any other immunomodulating or disease modifying therapy after completion of the TG1101-RMS201 trial * Pregnant or nursing mothers
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Papers
Loading reviews and guidelines…
Linked trials
Extended by
TG1101-RMS303Phase 3 · Running, not recruiting
Links found where a registry record names another trial's registry number.
Related trials
- Operetta III
Phase 2 · Not yet recruiting
Still running
- SOLI
Recruiting
Still running
- SONATA-MS
Recruiting
Still running
- HiHat
Phase 2 · Recruiting
Still running
- REDIFINE MS
Recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
History
Started
Jun 2017
Main results due
Nov 2022
Finished
Nov 2022
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error